Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 178 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 2 of 2 entries Show 5 more changesShow less
    • Study completion pushed from Sep 18, 2026 to Sep 18, 2027
    • Eligibility criteria expanded, about 36 words
    • Secondary endpoints: details revised at 2 of 3 entries
    • Study description revised
    • Site details revised at 9 of 174 sites
  2. Study sites: 175 to 174v177
  3. Study sites revised (175)v176
  4. Study sites revised (175)v175
  5. Study sites revised (175)v174
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites revised (175)v173
  2. Study sites: 176 to 175v172
  3. Study sites revised (176)v171
  4. Study sites: 177 to 176v170
  5. Re-verified, no change to tracked fieldsv169
  6. Study sites revised (177)v168
  7. Study completion date: Sep 19, 2025 to Sep 18, 2026v167
  8. Study sites revised (177)v166
  9. Study Status, Contacts/Locationsv165
  10. Study sites revised (177)v164
  11. Study sites revised (177)v163
  12. Study sites revised (177)v162
  13. Study sites: 178 to 177v161
  14. Study sites revised (178)v160
  15. Study sites: 179 to 178v159
  16. Study sites revised (179)v158
  17. Study sites revised (179)v157
  18. Study completion date: Sep 21, 2024 to Sep 19, 2025v156
  19. Re-verified, no change to tracked fieldsv155
  20. Study sites revised (179)v154
  21. Study sites revised (179)v153
  22. Study sites revised (179)v152
  23. Enrollment target: 29 to 28
    • Study sites revised (179)
    v151
  24. Results first posted: Mar 5, 2024
    • Primary endpoints: 3 to 2
    • Secondary endpoints expanded, about 10 words
    v150
  25. Start date: Nov 3, 2017 to Jul 16, 2018
    • Study completion date: Oct 24, 2023 to Sep 21, 2024
    v149
  26. Re-verified, no change to tracked fieldsv148
  27. Study sites revised (179)v147
  28. Study sites revised (179)v146
  29. Study sites revised (179)v145
  30. Re-verified, no change to tracked fieldsv144
  31. Study sites revised (179)v143
  32. Enrollment target: estimated 24 to confirmed 29
    • Study completion date: Oct 1, 2022 to Oct 24, 2023
    v142
  33. Study sites revised (179)v141
  34. Study sites revised (179)v140
  35. 5 versions Re-verified since Apr 23, 2022, no change to tracked fieldsv135-v139
  36. Study sites revised (179)v134
  37. Study sites revised (179)v133
  38. Primary and study completion dates: Oct 1, 2021 to Oct 1, 2022v132
  39. 3 versions Re-verified since Jul 13, 2021, no change to tracked fieldsv129-v131
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase I pilot trial studies how well atezolizumab, pemetrexed disodium, cisplatin, and surgery with or without radiation therapy works in treating patients with stage I-III pleural malignant mesothelioma. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab, pemetrexed disodium, and cisplatin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving atezolizumab after surgery may kill any remaining tumor cells.
Trial Details
NCT Number NCT03228537
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IB Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage II Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage III Pleural Diffuse Malignant Mesothelioma AJCC v7
Related terms Mesothelioma, Malignant
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov